Tailored Individualised Therapy To Improve Clinical Outcomes
Our Centre is developing emerging, novel approaches to optimise antimicrobial use and sustain the effectiveness of these drugs in the face of increasing antimicrobial resistance (AMR) and the absence of new treatments.
We provide state-of-the-art research facilities and consolidates multidisciplinary academic excellence, clinical expertise, Imperial’s NIHR/Wellcome Clinical Research Facility (CRF), and partnerships with the NHS to support and deliver innovative research on antimicrobial optimisation and precision prescribing.
Our research includes:
- Development of rapid diagnostic solutions for the detection of infections and genes associated with antimicrobial resistance to guide treatment decisions and optimise antimicrobial use.
- Real-time biosensor technologies to monitor antimicrobial concentrations and disease biomarkers within the body on microneedle or on a Point of Care devices.
- Utilising artificial intelligence and machine learning to assist with infection detection, diagnosis, clinical decision making and providing effective guidance on antimicrobial selection, timing and concentrations to use, especially in vulnerable patient populations.
CAMO Seed Projects
Optimising antibiotic therapy in multimorbidity using intelligent, personalised clinical decision support systems
Continuous minimally-invasive sensing of lactate for individual risk-stratification and antimicrobial optimisation
Improving antimicrobial treatment of CNS infection through development & validation of peripheral real-time monitoring and machine learning algorithms
Improving antifungal treatment and addressing antifungal resistance in cystic fibrosis-(CF) related fungal lung disease